Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand ...

Investors burned by President Trump’s trade fight now have to contend with a spending megabill that risks swelling the ...

The Moody’s announcement sent the yield on a 30-year Treasury bond to a high of 5.01% at one point on Monday. Bond yields ...

Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

The latest warnings from JPMorgan’s Jamie Dimon on geopolitical risks and tariffs have become par for the course.While he ...

The private equity owner of Northwind Midstream is exploring a potential sale of the Permian Basin gas infrastructure ...

Thank you for your interest in Regeneron and welcome to our first quarter 2025 earnings conference call. An archive and transcript of this call will be available on Regeneron's Investor Relations ...

Thank you for your interest in Regeneron, and welcome to our first quarter 2025 earnings conference call. An archive and transcript of this call will be available on Regeneron's Investor Relations ...

I will now turn the call over to Ryan Crowe, Senior Vice President, Investor relations. You may begin. Thank you, Josh. Good morning, good afternoon, and good evening to everyone listening around the ...

Wall Street stocks edged higher Monday (May 19) after shrugging off a spike in US Treasury bond yields following Moody's ...

The FTSE 100 , US markets and European stocks floundered on Monday, despite a new deal struck between the EU and UK, as ...